CRISPR Gene Editing Patent Dispute: The Fierce Battle Behind Scientific Innovation

"Who has the right to cut genes first?" At the heart of the most heated debate in biotechnology, CRISPR is the focal point.

Hello, if you've been following science news lately, you've probably heard of CRISPR. Initially, I thought it was just a technical debate among scientists, but it turns out to be a massive patent battle that could change the entire global biotechnology industry. A few days ago, I heard someone in a community say, "If you know who first used CRISPR, you can predict the direction of vaccine stocks," and I became deeply immersed in this issue. Today, I’ll break down the core of this controversy for you.

Table of Contents

What is CRISPR Technology? Who Developed It First: The Invention Origin Dispute The Course of the Patent War Impact on the Biotechnology Industry Significance of the Verdict and Future Issues Ethical Considerations and the Future of the Technology

What is CRISPR Technology?

CRISPR is a revolutionary gene-editing technology known as the “gene scissors.” Its full name, ‘Clustered Regularly Interspaced Short Palindromic Repeats,’ refers to a biological tool that allows precise cutting or replacement of specific genes. The biggest advantages of this technology are efficiency and precision, making it much cheaper, faster, and simpler compared to traditional gene-editing methods. Thanks to its applications, it is used in everything from previously incurable genetic diseases to cancer research and even COVID-19 studies. The ability to modify DNA as easily as editing a cell in Excel is truly groundbreaking.

Who Developed It First: The Invention Origin Dispute

The most heated debate was about “who first developed the CRISPR technology.” A fierce legal battle ensued between two female scientists, Jennifer Doudna (UC Berkeley) and Emmanuelle Charpentier (Max Planck), and Feng Zhang (MIT Broad Institute). The key issue was whether the technology’s application to ‘bacteria’ or ‘human cells’ affected the scope of the patent rights.

Inventor	Key Contributions	Patent Affiliation
Jennifer Doudna & Emmanuelle Charpentier	Clarified the basic principles of CRISPR in bacteria	UC Berkeley, Max Planck Institute
Feng Zhang	First to apply CRISPR technology to human cells	MIT Broad Institute

The Course of the Patent War

The dispute went on for years between the U.S. Patent Office and the international patent organizations. The parties compared hundreds of pages of documents, experimental evidence, and even the timing of paper submissions to determine who successfully applied the technology first. The legal battle was not just about patent rights but also involved billions of dollars worth of industrial interests.

• 2012: Doudna and Charpentier team publish basic principles in Science journal
• 2013: Feng Zhang team publishes paper on human cell application in Cell journal
• 2016–2022: Ongoing patent challenges and appeals at the U.S. Patent Office

Impact on the Biotechnology Industry

The CRISPR patent dispute has had a significant impact on the biotechnology industry. Depending on which patent a research lab or company has access to, the costs and availability of the technology vary, affecting valuations of biotech startups. Investors also made their decisions on which technology to bet on based on patent ownership.

Significance of the Verdict and Future Issues

In 2022, the U.S. Patent Trial and Appeal Board granted priority to Feng Zhang’s team for the application of CRISPR technology to human cells, settling one side of the controversy. However, there are still overlapping patents regarding applications in bacteria and other organisms, leaving the legal structure of CRISPR technology’s use and licensing still complex.

Year	Key Verdict	Impact
2017	Broad Institute’s human cell patent granted	Technology commercialization by related companies
2022	UC Berkeley’s appeal dismissed	Reorganization of technology usage rights, license renegotiation

Ethical Considerations and the Future of the Technology

CRISPR has immense potential as a medical technology, but ethical debates are still ongoing. Concerns over human embryo modifications, genetic enhancement, and issues of accessibility and fairness remain unresolved. As the technology advances, it becomes increasingly important to strike a balance between what can be done and what should be done.

• Ethical debate over human embryo manipulation through gene editing
• Ambiguity between therapeutic uses and designer babies
• Disparities in healthcare access due to technology monopolies

Frequently Asked Questions (FAQ)

Q How does CRISPR edit genes?

A guide RNA locates the specific DNA position, and the Cas9 enzyme cuts that region, allowing for the removal or insertion of genes.

Q What was the core of the CRISPR patent dispute?

The main issue was the competition over who first successfully applied CRISPR technology to human cells.

Q What advantages does having the patent provide for commercialization?

Companies that want to use the technology must pay royalties, and exclusive rights to the patent make market entry easier, generating huge profits.

Q Can CRISPR be applied to humans right now?

Some diseases are being treated through clinical trials, but due to ethical concerns and safety tests, its use is still limited.

Q Do people need a license to use CRISPR technology?

Yes, they need to get an official license from the patent-holding institution, and royalties are set based on the usage scope.

Q How will CRISPR technology develop in the future?

The focus will be on improving precision, reducing off-target effects, and establishing ethical guidelines, aiming to ensure safety and public benefit.

In Conclusion: The Progress of Science and the Battle for Rights Behind It

CRISPR is truly an amazing technology. But with its potential came fierce competition over who gets to use and own it. I believe that for science to progress in a way that benefits humanity, it's crucial that the patent system operates fairly. Watching this situation unfold, I realized that while technology itself is neutral, the people and systems that wield it can greatly change its outcomes. What do you think? Share your thoughts in the comments. This is a moment when science, society, and law intersect, and we all need to reflect on it together.

Shin Hae-chul's Medical Malpractice Lawsuit: The Last Story Heavier Than Music

His music transcended generations, but his final moment was far too real.

Hello, everyone. Today, I write with a heavy heart. I grew up listening to Shin Hae-chul, whose name was more than just a musician—it was the voice of an entire generation. But in 2014, shocking news broke: he suddenly passed away after undergoing a routine stomach surgery. It seemed too much like a medical accident, but there were too many questions, and eventually, the case went to court. Today, we’ll discuss the messages left by Shin Hae-chul’s medical malpractice lawsuit and what our society needs to reflect on.

Table of Contents

Incident Overview: The Start of a Routine Surgery The Legal Battle: How Far Does the Responsibility of the Medical Staff Go? Public Shock and Social Reactions Voices from the Family and the Journey Toward the Truth The Verdict and the Impact on the Medical Field Reflections on Medical Ethics We Need to Revisit

Incident Overview: The Start of a Routine Surgery

In October 2014, Shin Hae-chul underwent abdominal surgery, including adhesiolysis at a hospital in Seoul. The surgery was initially known as a routine procedure, but afterward, he complained of abdominal and chest pain and was rushed to the emergency room in a state of cardiac arrest. Tragically, he never regained consciousness. After his death, it was revealed that the surgical team had caused a bowel perforation during the procedure, which led to peritonitis, sparking allegations of medical malpractice.

The Legal Battle: How Far Does the Responsibility of the Medical Staff Go?

Year	Main Content	Result
2014	Investigation begins immediately after death	Allegations of medical malpractice raised
2017	Doctor found guilty	Sentence of 1 year in prison with 2 years of probation

Public Shock and Social Reactions

Shin Hae-chul's sudden death shocked not only his fans but also the medical community. The public's reaction went beyond mourning and evolved into anger over why such incidents keep happening.

• Increased demand for reforms in medical malpractice systems
• Proposals for stronger patient protection and medical transparency laws
• The #RememberTheKing campaign spread on social media

Voices from the Family and the Journey Toward the Truth

Shin Hae-chul's wife, Yoon Won-hee, bravely stepped forward to uncover the truth behind his death. Her fight for justice wasn’t just an expression of anger, but a sincere desire to ensure that no one else would suffer the same fate. She took part in press conferences and national assembly discussions, asking, "What if it had been another patient instead of Shin Hae-chul?" That question resonated with everyone.

The Verdict and the Impact on the Medical Field

Impact Area	Changes
Medical Law	Expansion of mandatory medical record disclosure and revisions to medical dispute settlement laws
Physician Responsibility	Strengthened patient consent procedures and legal obligations for disclosure

Reflections on Medical Ethics We Need to Revisit

The Shin Hae-chul case was not just a personal tragedy; it was a wake-up call regarding the flaws in the medical system and the need for ethical reflection. Here are some key issues we must revisit.

1. Strengthening patients' right to know and the duty to explain
2. Improving post-surgery care systems
3. Ensuring transparency and accountability in case of medical malpractice
4. Expanding the accuracy and preservation duties of medical records

Frequently Asked Questions (FAQ)

Q What surgery did Shin Hae-chul undergo?

He underwent abdominal surgery including adhesiolysis and gastric reduction surgery. Though it was a relatively common procedure, the outcome was fatal.

Q Was the medical malpractice confirmed?

The court recognized the doctor's negligence and sentenced him to prison, though the sentence was suspended. The malpractice was determined based on legal judgment.

Q What actions did the family take?

Shin Hae-chul's wife, Yoon Won-hee, continuously advocated for medical system reforms and demanded a responsible apology. She participated in legislative activities related to this issue.

Q Were any systems changed because of this case?

There was an expansion in the range of medical record disclosures and stronger obligations to explain procedures, and these discussions led to some legal reforms.

Q What punishment did the doctor face?

He was sentenced to 1 year in prison with 2 years of probation, and he was also charged with violating medical laws. However, the issue of maintaining his medical license remains a point of controversy.

Q What message did this case send to the medical field?

The case reminded us of the importance of transparency, proper explanation, and accountability in medical practices, and underscored the need for humility in the face of human life.

Questions Left for Those Who Remain

Shin Hae-chul's death was not just the loss of one musician. It raised fundamental questions about the medical system we trust and rely on. Medical practice, dealing with human life, carries an enormous weight, and mistakes should never be tolerated. Through this post, if it made you reflect on society's responsibility for medical malpractice and the importance of prevention, I believe that is a small step in honoring his legacy. Your thoughts are always welcome, so feel free to share in the comments.

Human Genome Project Patent Dispute – Who Owns Genetic Information?

At the moment humanity’s blueprint was deciphered, science opened knowledge, and corporations sought ownership.

Hello. Today, we will explore the Human Genome Project (HGP), one of the boldest attempts in the history of life sciences, and the gene patent disputes surrounding it. This large-scale scientific project, aimed at decoding the entire human genome, initially sought to build a public database for humanity. However, as private companies rushed to file patents on gene sequences, a dramatic clash between pure science and market logic unfolded. Let's delve into the complex tug-of-war between public and private interests over the blueprint of life.

1. What is the Human Genome Project?

The Human Genome Project (HGP) was an international scientific collaboration launched in 1990, led by the U.S. government, to decode all human genetic information. The goal was to sequence the entire human genome, consisting of about 3 billion base pairs, and register it in a public database.

Completed in 2003, the project marked a revolutionary turning point in biology, medicine, and the biotech industry. It triggered a full-scale start to gene-based research in areas such as cancer, genetic diseases, and drug development.

2. Competition with Celera Genomics

In 1998, the biotech company Celera Genomics began an independent, privately funded effort to decode the human genome, which sparked tensions. Led by Dr. Craig Venter, Celera claimed it could complete the sequencing faster than the government project using an efficient method called "shotgun sequencing."

Category	Human Genome Project	Celera Genomics
Funding	Public budget (USA, EU, Japan, etc.)	Private investment (venture capital)
Technology	Targeted sequencing	Shotgun sequencing (random whole-genome)
Goal	Build a public genome database	Commercialize genetic information

3. Gene Patent Filing Controversy

Based on its genome sequencing data, Celera filed thousands of patents for gene sequences and predicted gene functions. This move provoked fierce backlash from academia and public institutions, arguing that “patenting naturally occurring genes amounts to the privatization of public assets.”

• Patent on natural substances may infringe constitutional rights
• Restricts access by other researchers and discourages research
• Monopoly pricing and commercialization of diagnostic services via patents

4. Public Data vs. Corporate Monopoly

Celera’s gene patent strategy was seen as a case of extreme conflict between public and private interests. The public HGP camp insisted that “all genetic information must be freely accessible to everyone” and accelerated the release of data to neutralize preemptive patent filings.

Celera, on the other hand, justified its actions by citing research costs and competitive edge. It monetized its own database and attempted to sell access exclusively to pharmaceutical and medical firms. This clash grew into a broader debate: “Should knowledge be shared or monetized?”

5. Court Rulings and Policy Changes

In 2013, the U.S. Supreme Court delivered a groundbreaking ruling. In the well-known Myriad Genetics case, the Court declared that “naturally occurring human genes cannot be patented,” putting a brake on common gene patent practices. This was a major blow to commercial efforts by Celera and others.

Case	Decision	Significance
Myriad Genetics v. Association for Molecular Pathology (2013)	Invalidated BRCA1 and BRCA2 gene patents	Declared that natural genes are not patentable
HGP follow-up policy (NIH)	Mandatory public disclosure of genome data	Strengthened public access to research data

6. Who Owns Genetic Information?

The genome patent dispute is not just a thing of the past — it remains a relevant debate today in an era of personalized medicine and large-scale genetic data analysis. Who owns an individual’s DNA information? Can companies profit from it? To what extent should the public sector be involved?

• Are genome datasets a shared human asset or personal property?
• Is it justifiable to commercialize data generated with public funding?
• How do we balance profits of genetic testing companies with personal privacy?

The question of who owns human genes is one that will continue to challenge us in the future.

6. Who Owns Genetic Information?

The genome patent dispute is not just a thing of the past but remains an ongoing debate, especially as genome-based personalized medicine and big data gene analysis continue to expand today. Who owns personal DNA information? Can corporations profit from it? Where should the public’s involvement end?

• Is genomic data a shared human asset or individual property?
• Is it legitimate for publicly funded data to be commercialized?
• How should the balance between corporate profits and individual privacy in genetic testing companies be managed?

The debate over who owns human genetic information will continue for the foreseeable future.

Frequently Asked Questions (FAQ)

Q What were the major achievements of the Human Genome Project?

It decoded the basic sequence of the human genome, consisting of 3 billion base pairs, and made this data publicly available, providing a foundation for life sciences research.

Q Can genes be patented?

In many countries, including the U.S., naturally occurring gene sequences cannot be patented, but artificially modified genes or applied technologies are sometimes patented under certain conditions.

Q Does Celera Genomics still exist?

No, Celera merged with other biotech companies and is no longer an independent entity. However, its model of gene commercialization influenced modern genetic testing firms.

Q Why is the Myriad ruling important?

This ruling was a pivotal moment in stopping the practice of patenting natural genes. It has significantly influenced the push for public access to life sciences data.

Q Is all genetic data publicly available?

Most genome data produced by public institutions is available, but some private companies' personalized analysis data or commercial algorithms are not publicly accessible.

Q Will gene patents completely disappear in the future?

While they may not completely disappear, the focus of patents is shifting from natural genes to applications such as gene technologies, diagnostic kits, and data algorithms. Legal and ethical standards continue to evolve.

Who Owns the Genome – Questioning the Future of Science and Public Interest

The Human Genome Project and the gene patent dispute are not merely scientific issues; they have reshaped our thinking about knowledge sharing and ownership and the philosophy of public access. Is genetic information a shared asset for all humanity, or the property of the corporations that invested in it? This question continues today in the realms of genetic testing services, life insurance, and personalized medicine. As the advances in life sciences grow, we must remember that the foundation of this progress—the information—should remain open to all.

Mutant Mouse Patent Dispute – The Border Between Biotechnology and Intellectual Property

Could a single mouse ignite an international patent war? A tense tug-of-war between science and law over life.

Hello! Today’s case may be unfamiliar, but it shook both the biotechnology and legal communities — the Mutant Mouse Patent Dispute. This genetically engineered mouse, developed for disease research, has been widely used in laboratories around the world. But a fierce battle over the 'ownership' of this mouse has arisen among universities, governments, and corporations. This case goes beyond experimental animals and poses the philosophical question: Can living organisms be patented? Let’s dive into this fascinating and important story.

Table of Contents

1. What is OncoMouse? 2. Patent Filing and Harvard's Ownership Claim 3. Disputes Over Patent Recognition in Different Countries 4. Ethical Issues in Life Patents 5. The Dilemma Between Scientific Research and Commercialization 6. What is the Future of Biotechnology Patents?

1. What is OncoMouse?

OncoMouse is a genetically modified laboratory mouse developed by a research team at Harvard University. This mouse was designed by inserting specific genes so that cancer develops naturally, making it extremely useful in cancer research. It became the standard model in the biomedical field worldwide, especially in studies related to breast and skin cancers.

However, controversy arose over whether this mouse could be considered a “patentable subject”. The question was whether a genetically altered organism could be legally recognized as intellectual property.

2. Patent Filing and Harvard's Ownership Claim

In 1984, Harvard University filed the first patent application for a living organism with the United States Patent and Trademark Office (USPTO). In 1988, the USPTO approved the patent, stating that “living organisms artificially created through genetic modification can be patented.” This marked the first animal patent in U.S. history and caused a major stir.

Item	Details
Patent Name	Transgenic non-human mammal (OncoMouse)
Applicant	Harvard University (Inventor: Philip Leder)
Patent Granted Year	1988 (U.S.), 1992 (some European countries)
Controversy	Ownership of living organisms, expanded ethical debates

3. Disputes Over Patent Recognition in Different Countries

While the OncoMouse patent was filed in many countries after the U.S., each nation produced different outcomes. Some recognized the patent, while others rejected or limited it for ethical reasons.

• United States: First approval, sparked biotechnology industry growth
• Canada: Recognized DNA manipulation, but not patenting the animal itself
• European Patent Office (EPO): Approved with limitation to “mouse” after ethical debates (1992)
• Germany, Netherlands: Rejected or conditionally approved based on animal welfare laws

These international differences reflect the philosophical variations in how legal status is granted to living organisms and in perceptions of scientific technology.

4. Ethical Issues in Life Patents

The OncoMouse patent raised a fundamental question beyond intellectual property: Can humans “own” or “commercialize” life? Granting a patent on an entire living being—not just a part—has been criticized from the perspective of animal rights and bioethics.

Animal rights groups and ethicists continuously questioned whether it is truly justifiable for genetically modified animals to suffer and be sacrificed. In some countries, there were even discussions of legislation to ban life patents altogether.

5. The Dilemma Between Scientific Research and Commercialization

After the OncoMouse patent, disputes emerged between universities/research institutions and biotech companies over profit sharing and access limitations. Harvard licensed the patent to DuPont for commercialization, and as a result, researchers had to pay usage fees to use the mouse.

Field	Impact
Public Research	Concerns over restricted research due to licensing fees
Commercialization	Provided exclusive profit opportunities to patent holders
International Cooperation	Sparked conflicts between nations due to differences in patent coverage

6. What is the Future of Biotechnology Patents?

With the emergence of CRISPR, patents for gene-edited life forms are expected to become even more complex and crucial. As patent scopes expand to include AI-designed organisms, synthetic life forms, and genetic data databases, balancing law and ethics has become more important than ever.

• Could synthetic biology also become subject to patents?
• Rising issues over ownership of genetic data
• Growing need for mechanisms ensuring global public research access

Ultimately, we face the question: “Who defines life, and who is entitled to own it?”

Frequently Asked Questions (FAQ)

Q What diseases is OncoMouse used to study?

It is primarily used in research on various types of cancer, including breast cancer, skin cancer, and colon cancer. It is a highly useful model for studying tumor development and treatment mechanisms.

Q Can living organisms be patented?

In some countries, yes—but not all. Patents are generally granted only when there is a clear artificial intervention, such as genetic modification.

Q Who is allowed to purchase OncoMouse?

DuPont, which held the license from Harvard, sold it to research institutions, universities, and pharmaceutical companies. Commercial use required a separate licensing agreement.

Q Why did some countries reject the patent?

Mainly due to ethical reasons. Many countries considered human ownership over living beings unjust or found it incompatible with animal welfare laws.

Q Do patents hinder research?

They can. Public research institutions and nonprofits have raised concerns that legal and financial barriers make access to such technologies difficult.

Q Will patents on living organisms continue to increase?

The potential is high with advancements in gene-editing technologies, but sustainable systems will require more refined legal and ethical standards.

Reconsidering the Boundaries of Rights and Ownership Over Life

The OncoMouse patent dispute isn’t merely a clash between science and intellectual property—it fundamentally asks how we define and regard life. Should life be viewed solely as a tool, or should it be treated with respect? As genetic technologies evolve, this debate will intensify. I hope today’s story inspires reflection on the future of biotechnology. Where do your thoughts lie?

Thalidomide Birth Defect Cases: The Worst Disaster in Medical History

"Just one sedative pill changed a life." The drug thalidomide, which caused thousands of babies worldwide to be born without arms or legs. Let’s revisit this tragedy.

Hello. If you're someone interested in pharmaceuticals and bioethics, you may have heard of the thalidomide incident. When I first encountered this case, I was both shocked and wondering, “How could such a thing happen?”

Today, we will carefully look into the full story of the thalidomide disaster that shocked the world in the 1950s–60s, the babies born with birth defects, and how it transformed drug regulation afterwards.

Contents

1. Development and Purpose of Thalidomide 2. Birth Defect Cases After Use by Pregnant Women 3. Global Reactions and Sales Bans 4. Lives of Victimized Children and Legal Action 5. Impact on Drug Regulation 6. Ethical Lessons We Must Remember

1. Development and Purpose of Thalidomide

Thalidomide was a sleeping pill and sedative developed in 1957 by the German pharmaceutical company Grünenthal. At the time, it was promoted as a "safe drug" effective for relieving morning sickness, insomnia, and anxiety in pregnant women.

Thanks to marketing that claimed it had fewer side effects than existing sleeping pills, it was widely distributed across 46 countries in Europe, Asia, and South America by the early 1960s. Over 14 million tablets were sold in just one year.

2. Birth Defect Cases After Use by Pregnant Women

A few months after the drug was released, cases of babies born without arms or legs began to be reported around the world. This condition, known as "phocomelia," was rare at the time, and its cause was not yet understood.

However, studies revealed that if thalidomide was taken between the 4th and 6th week of pregnancy, the fetus’s development was severely impaired. The drug interfered with the formation of blood vessels in the fetus, leading to incomplete development of limbs and organs.

• Phocomelia (shortened or absent limbs)
• Hearing and visual impairments
• Heart and kidney defects
• Abnormal internal organ development

Ultimately, it is estimated that over 10,000 babies were born with birth defects due to thalidomide worldwide. This remains one of the worst pharmaceutical disasters in history.

3. Global Response and Sales Suspension

As reports of birth defects increased, Germany, the UK, Australia, and other countries swiftly launched investigations. By the end of 1961, thalidomide was recalled and sales were suspended worldwide.

Country	Date of Suspension	Remarks
Germany	November 1961	Original developer; class-action lawsuits followed
United Kingdom	December 1961	Many pharmacies voluntarily destroyed stock
United States	Approval Withheld	Blocked by FDA pharmacist Dr. Frances Kelsey

In particular, Dr. Frances Kelsey of the FDA was praised for refusing to approve thalidomide in the U.S., preventing large-scale damage in the country.

4. The Lives of Victims and Legal Actions

Children born to mothers who took thalidomide faced lifelong physical pain and social discrimination. Born without arms or legs, they were in dire need of assistive devices, rehabilitation, and emotional support.

• Multiple surgeries, use of wheelchairs, prosthetic arms and legs
• Discrimination in education and employment opportunities
• Class-action lawsuits for compensation and government support

Victims filed group lawsuits against pharmaceutical companies and governments in Germany, the UK, and Japan. Some received lifetime annuity-style compensation, but many argue that apologies and reparations remain insufficient.

5. Impact on Drug Regulation

Following this tragedy, global pharmaceutical policies shifted dramatically toward a "safety-first" framework.

New Regulations	Details
Strengthened FDA Clinical Trial System	Drug approval only after animal testing and pregnancy-related safety checks
Mandatory Pre-Approval by Drug Authorities	All pharmaceuticals subject to approval prior to market release
Pregnancy Risk Category Labeling	Drugs must display safety categories ranging from A to X

These regulations marked a turning point in drug approval systems, and even today, thalidomide remains a critical lesson in managing medications for pregnant women.

6. Bioethical Lessons We Must Remember

The thalidomide tragedy was not merely a "drug failure" but a defining moment that questioned the responsibility and ethics of the pharmaceutical industry.

1. Drugs must undergo thorough safety testing for long-term effects on humans and fetuses before release.
2. Ethical responsibility must be upheld throughout clinical trials, approval, and distribution.
3. In the event of harm, swift compensation and apology are essential to restore public trust.

Remembering this tragedy is the starting point for safeguarding today’s lives and tomorrow’s health.

Frequently Asked Questions (FAQ)

Q What was the original purpose of thalidomide?

It was initially developed as a sleeping aid and tranquilizer, widely used to alleviate morning sickness in pregnant women.

Q What types of deformities occurred?

Most common was phocomelia—babies born with very short or missing limbs. There were also cases of heart, hearing, and kidney defects.

Q How many children were affected?

Over 10,000 cases were officially reported worldwide. Unreported cases could make the actual number significantly higher.

Q Why wasn’t thalidomide sold in the U.S.?

Because FDA pharmacologist Dr. Frances Kelsey insisted on withholding approval, thalidomide was never officially released in the U.S., avoiding widespread harm.

Q What new regulations were introduced after the incident?

Clinical trials for pregnant women became mandatory, drug approval systems were strengthened, and pregnancy safety categories (A–X) were introduced.

In Conclusion: The Weight of Responsibility in Handling Life

The thalidomide tragedy wasn’t just a drug accident but a disaster that reshaped drug safety and bioethics standards. A single pill changed thousands of lives, and the shock still reverberates through the medical community.

We must remember this story for a clear reason. Choices tied to life require rigorous verification and transparency, and that responsibility belongs not only to pharmaceutical companies, but to society as a whole.

Remembering the past is the beginning of a better future. Let us all carry the lessons of thalidomide as a standard we must uphold to prevent such tragedies from recurring.